A heart transplant is an operation in which the diseased heart in a person is replaced with a healthy heart from a deceased donor. Ninety percent of heart transplants are performed on patients with end-stage heart failure.
Heart failure is a condition in which the heart is damaged or weakened and can't pump enough blood to meet the body's needs. "End-stage" means the condition has become so severe that all treatments, other than heart transplant, have failed.
A southern Taiwan-based National Cheng Kung University (NCKU) research team has identified the critical time period and a drug as treatment for cardiac repairing, the university revealed recently at a press conference.
Heart transplantation continues to be the "gold standard" treatment for end-stage heart failure, and a large number of patients now live 20 years or more after surgery, according to a study in the February 2014 issue of The Annals of Thoracic Surgery.
Infants and children who undergo heart transplantation are experiencing good outcomes after surgery and may expect to live beyond 15 years post-surgery with reasonable cardiac function and quality of life, according to a study released today at the 50th Annual Meeting of The Society of Thoracic Surgeons.
Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.
Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism within the heart, measured using a noninvasive magnetic resonance imaging test, is a significant predictor of clinical outcomes, independent of a patient's symptoms or the strength of the heart's ability to pump blood, known as the ejection fraction.
Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection.
New research from Karolinska Institutet in Sweden shows that patients with heart failure have high mortality and often are undertreated. According to a study, published in the scientific periodical JACC, many more of these patients would benefit from advanced treatment by heart specialists - something that could be decided by a simple evaluation of five common risk factors for early death due to heart failure.
A long-term study of children with a complex heart condition called hypertrophic cardiomyopathy (HCM) found that the risk of death or need for immediate listing for heart transplantation was greatest for those who developed this disease as infants with congestive heart failure and for children who also had selective inborn errors of metabolism, a group of rare genetic disorders in which one or more of the body's key metabolic processes are disrupted.
US scientists have identified key risk factors that predict which children with hypertrophic cardiomyopathy, the most common cause of sudden death in young people, are at greatest risk of death or need for heart transplant—information that could help physicians figure out who will benefit most from transplant surgery.
Cardiac surgeons and cardiologists at the University of Maryland Heart Center are part of a multi-center clinical trial evaluating the efficacy of powering heart pumps through a skull-based connector behind the ear. Typically, these devices for patients with severe heart failure are energized through an electrical cord connected at an abdominal site, where potentially deadly infections can develop.
Human hearts which are not used each year because they are deemed unsuitable for an organ transplant could get a second chance to save a life, with the help of new research taking place in the North East.
The 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy- developed in collaboration with the European Heart Rhythm Association, have created a new classification system for bradyarrhythmias according to mechanisms rather than aetiology.
Diaxonhit, the leading French provider of specialty diagnostic solutions, and XDx, Inc., a U.S. molecular diagnostics company focused on non-invasive tests for transplantation and autoimmune disease, announced today that they have entered into a memorandum of agreement for the exclusive license to market and perform AlloMap Molecular Expression Testing (AlloMap) in Europe.
UCLA researchers examining outcomes for advanced heart-failure patients over the past two decades have found that, coinciding with the increased availability and use of new therapies, overall mortality has decreased and sudden cardiac death, caused by the rapid onset of severe abnormal heart rhythms, has declined.
The Heart Failure Congress 2013 promises more science than ever this year, with a record number of abstracts submitted. The congress takes place 25-28 May at the Centro de Congressos de Lisboa in Lisbon, Portugal.
For the third year in a row, the Cedars-Sinai Heart Institute and Comprehensive Transplant Center performed more adult heart transplants than any other U.S. medical center, according to statistics compiled by the United Network for Organ Sharing, the nonprofit organization that manages the nation's transplant system.
Survival following heart transplantation is associated with several patient characteristics, including patient education, higher social and economic satisfaction, and patient adherence with medications, according to a study published in the March 2013 issue of The Annals of Thoracic Surgery.
Novartis announced today that the US Food and Drug Administration (FDA) has approved Zortress (everolimus) for the prophylaxis of organ rejection in adult patients receiving a liver transplant.
Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that the U.S. Food and Drug Administration has granted an Investigational Device Exemption to commence the REVIVE-IT study utilizing the HeartMate II Left Ventricular Assist System.
Kevin Riepl arrived at Cedars-Sinai in October 2010, suffering from sudden heart failure that left him fighting for his life. Surgeons swiftly installed a heart pump and later transplanted a new heart, saving his life and turning him into an unexpected ambassador for organ donation.